Compare Ginkgo Bioworks Holdings Inc (DNA) vs IQIYI Inc - ADR (IQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs IQIYI Inc - ADR — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.41 (market cap $505.73M), while IQIYI Inc - ADR trades at $1.34 (market cap $1.30B). The key difference: IQIYI Inc - ADR is far larger — about 2.6× Ginkgo Bioworks Holdings Inc's market cap. Which is the better fit depends on your goals.
| DNA | IQ | |
|---|---|---|
Market Cap | $505.73M | $1.30B |
Sector | Health | Media |
52-Week High | $16.14 | $2.79 |
52-Week Low | $5.48 | $0.96 |
Enterprise Value | $607.68M | $2.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
IQ (iQIYI) trades at $1.33, down 2.21% today, with a bullish technical signal from moving averages but overbought RSI readings. Revenue declined to $27.29B in 2025, with a net loss of $206.31M, though the company beat EPS expectations in two recent quarters. Recent news highlights AI platform growth and executive changes, while analyst sentiment is mixed with 50% buy ratings.
The outlook hinges on AI-driven content innovation and cost management to reverse profitability challenges, but risks include intense competition and regulatory pressures in China. Upside potential exists if execution improves, yet near-term volatility may persist amid earnings uncertainty and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →
